Biochemical Engineering Special Interest Group
biological engineering professionals

Latest news

ADC startup NBE raises 20M from Novo Holdings

Novo Holdings has invested CHF 20 million ($20 million) in NBE Therapeutics, doubling the size of the startup’s series B round. NBE will use the money to start testing anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in solid tumor patients. NBE thinks its enzumatic approach to conjugation provides more control over where the payload is joined to the antibody than is possible with traditional chemical conjugation.

Latest news RSS feed

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).